Metformin lowers risk of long COVID
Treatment with the diabetes drug metformin immediately after testing positive for the SARS-CoV-2 virus lowers the risk of developing long COVID by 41%. Researchers reported this finding on… read more.
Treatment with the diabetes drug metformin immediately after testing positive for the SARS-CoV-2 virus lowers the risk of developing long COVID by 41%. Researchers reported this finding on… read more.
Novartis presents positive primary endpoint data from the pivotal Phase III NATALEE trial at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting . Data showed that… read more.
Pre-term and low birthweight infants have fewer fractures in childhood than full-term and normal-weight newborns, according to a new a study from the University of Eastern Finland and… read more.
Amgen announced the presentation of new data from the CodeBreaK clinical trial program, the most comprehensive global development program in patients with KRAS G12C-mutated cancers, at the American… read more.
TG Therapeutics announced that the European Commission (EC) has granted approval of Briumvi (ublituximab xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS)… read more.
In an international study co-led by UCLA, scientists have shown that a new targeted therapy drug can extend the amount of time people with a subtype of glioma… read more.
Merck known as MSD outside of the United States and Canada, announced positive results from the pivotal Phase III KEYNOTE-671 trial evaluating Keytruda, Merck’s anti-PD-1 therapy, as a… read more.
Neurocrine Biosciences, Inc. presented findings from a meta-analysis of three long-term studies evaluating Ingrezza (valbenazine) capsules that demonstrated substantial and sustained improvements in tardive dyskinesia (TD) in adults… read more.
Portable ultrasound devices could provide an alternative to x-ray machines for diagnosing forearm fractures in children in a move that could alleviate waiting times for families in hospital… read more.
The results of a new clinical trial suggest that the first drug therapy to slow the progression of nearsightedness in kids could be on the horizon. The three-year… read more.
– Primary results of the FROZEN-AF IDE trial with the POLARx Cryoablation System : Results from the global, prospective, non-randomized, single-arm FROZEN-AF IDE study of the POLARx Cryoablation… read more.
Clinician burnout and overwork are known to adversely affect patient safety and junior doctors may be particularly vulnerable, research suggests. The UK is facing a crisis in recruitment and retention… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.